Interested in the current clinical landscape on COPD? Read on for an overview on the latest clinical research based ondata analysis from TA Scan.
Chronic Obstructive Pulmonary Disease (COPD)is now one of thetop three causes of death worldwideand 80% of these deaths occur in low- and middle-income countries. More than 3 million people died of COPD, accounting for 6% of all deaths globally. (1)(2)
Some of the most importantrisk factorsassociated with COPD are tobacco smoke inhalation, exposure to environmental pollutants, chemical gases, fumes, and dust particles.
Global clinical landscape
4,533 trialsand2,234 sponsorshave brought together1,562 global investigators. The most active regions (in number of trials) areEurope(1,151),North America(451), andChina(128). With542 currently ongoing trials, of which 426 started during the COVID-19 pandemic, it is clear that this disease area has not lost any awareness.
Access TA Scan to quickly identify1,562 investigators, their collaborators, and2,863 clinical study sitesassociated with these ongoing trials. Most of these trials(85%)areacademically sponsored, and for the15%remaining, the topcommercial sponsorsare GSK(343 trials), Boehringer Ingelheim (276 trials), and AstraZeneca(213 trials).
Global distribution of investigators for ongoing COPD trials
Pharmacological therapies for COPD
Chronic Obstructive Pulmonary Disease has 218 drugs (registered globally) in TA Scan. There’s currently no cure for COPD, the available drugs are used to maintain the progression of the disease. The pie chartbelow shows thetop 10 drugsranked by number ofongoing trialsin COPD, going from117trials (Formoterol) to59trials (Fluticasone).
Top 10 COPD drugs: trial count
Two “new drugs” are in process for treating COPD and are in Phase 1-4: Umifenovir [NCT03851991] and gsk3923868 [NCT04585009]. In TA Scan you can see Gantt charts like the one below to get a time frame perspective for trials. You can hover over this chart to get key trial information, or click on the trial IDs to obtain more information through the trial drill-down.
Trial timeline for “new drugs” in COPD
Stay informed with TA Scan
Are you interested in knowing more aboutChronic Obstructive Pulmonary Diseaseor any of our other 525 therapeutic areas? Our clinical intelligence solution TA Scan allows you to extract relevant information and perform powerful analytics to get faster, data-driven insights for your business objectives ranging from Clinical Operations to Medical Affairs.